EX 101 - Guangzhou Excelmab
Alternative Names: EX-101 - Guangzhou ExcelmabLatest Information Update: 09 Oct 2023
At a glance
- Originator Guangzhou Excelmab
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 20 Sep 2023 Guangzhou ExcelMab plans a phase III trial of EX 101 for Breast cancer and Gastric cancer in USA and China, in the first quarter of 2025 (Guangzhou ExcelMab pipeline, September 2023)
- 11 Sep 2023 Guangzhou ExcelMab announces intention to submit BLA of EX 101 for Breast cancer and Gastric cancer in USA and China, in 2025 (Guangzhou ExcelMab pipeline, September 2023)
- 11 Sep 2023 Guangzhou ExcelMab plans a phase II trial of EX 101 for Breast cancer and Gastric cancer in USA and China, by the end of 2023(Guangzhou ExcelMab pipeline, September 2023)